Compare peptides side-by-side
Pick any two peptides to compare their evidence quality, FDA approval status, research scores, risks, and indications. All data sourced from the SmartPeptide library.
Educational only — not medical advice. SmartPeptide does not prescribe, diagnose, or treat. Always consult a licensed healthcare provider before using any peptide, supplement, medication, or protocol.
Semaglutide
GLP-1 receptor agonist with extensive Phase 3 trial data for type 2 diabetes and chronic weight management. Prescription-only in most jurisdictions.
Full pageStrong Phase 3 evidence (STEP 1–8 trials). STEP-1 (n=1,961) showed ~14.9% body-weight reduction at 68 weeks vs ~2.4% placebo. SELECT trial (n=17,604) showed reduced major adverse cardiovascular events in overweight/obese adults without diabetes.
Long-term effects beyond ~3–4 years of continuous use, optimal dosing for weight maintenance after stopping, and use in lean populations remain active research areas.
Pancreatitis risk, gallbladder events, contraindicated in personal/family history of medullary thyroid carcinoma.
Nausea, GI upset, constipation, fatigue. Discuss with a licensed prescriber.
CagriSema
Novo Nordisk's once-weekly combination of cagrilintide (an amylin analog) and semaglutide. Designed to combine appetite suppression (semaglutide) with satiety + meal-size regulation (cagrilintide). REDEFINE-1 Phase 3 showed ~22.7% weight loss at 68 weeks — strong but below pre-trial expectations.
Full pageREDEFINE-1 (Phase 3, n≈3,400, 68 weeks): mean weight reduction of ~22.7% on CagriSema vs. ~16.1% on semaglutide alone and ~3% on placebo. Cardiovascular outcomes trial REDEFINE-3 is ongoing. Awaiting full FDA submission package.
Not yet FDA-approved. The combination's performance vs. retatrutide in head-to-head comparisons is unknown. Optimal dosing and treatment duration are still being characterized. MASH and CV outcome data are pending.
GI side effects (class-typical for GLP-1 + amylin combination). Pancreatitis signal (rare, class warning), gallbladder events. Not yet FDA-approved — long-term safety still being characterized.
Nausea, vomiting, diarrhea, constipation, decreased appetite, injection-site reactions. The amylin component may add mild glucose-related effects.